Empagliflozin for treating chronic kidney disease (TA942)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Targeted-release budesonide for treating primary IgA nephropathy (TA937)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Difelikefalin for treating pruritus in people having haemodialysis (TA890)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Dapagliflozin for treating chronic kidney disease (TA775)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Immunosuppressive therapy for kidney transplant in adults (TA481)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 January 2009
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 January 2025
Sparsentan for treating primary IgA nephropathy [ID6308]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over TS ID 10761Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome TS ID 9998Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating complement 3 glomerulopathy ID6283Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating lupus nephritis ID 6420Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dapagliflozin for treating chronic kidney disease [ID6411]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC